Straits Times Index
3,080.40 +7.41 (+0.24%) Nikkei
33,455.31 -31.58 (-0.09%) Hang Seng
17,042.88 0.00 (0.00%) FTSE 100
7,453.75 +30.29 (+0.41%) Bitcoin USD
37,702.18 -37.45 (-0.10%) CMC Crypto 200
780.57 -3.08 (-0.39%)
Spyre Therapeutics, Inc. (AGLE)
- PR Newswire
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the "Company" or "Spyre"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol "SYRE". The name change follows the acquisition of privately held Spyre Therapeutics, Inc. by the Company in June of 2023. Named to reflect the Company's ambition to achieve new heights in efficacy and convenience of Inflamm
- PR Newswire
Aeglea BioTherapeutics Announces Grants of Inducement Awards
Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares of common stock and a grant of 18,912 restricted stock units to four non-executive employees as equity inducement awar
- PR Newswire
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced its third quarter 2023 financial results and provided program and corporate updates.
